Red Light Therapy Candidates: Which Hair Loss Responds
Which types of hair loss respond to red light therapy, and who is a good candidate?
The diagnosis decides everything here, and it's the step most people skip before they spend money. Red light isn't a general hair loss treatment, it's a treatment for one specific problem, and on the wrong scalp it does nothing no matter how faithfully you use it. Sorting out which category you're in is worth more than any comparison of devices.
Controlled trials of 16 to 26 weeks report gains of roughly 18 to 26 terminal hairs per square centimeter in androgenetic alopecia against gains of 2 to 9 in sham arms, with no comparable evidence in any other diagnosis.
Which hair loss condition has the strongest clinical evidence behind low level light therapy?
Androgenetic alopecia is the answer and it isn't close. Every device cleared in this category was cleared for hereditary pattern thinning, and the trials behind those clearances were randomized, double-blind, and measured against a dummy unit that looked and felt identical but emitted nothing therapeutic. That's a higher bar than almost anything else you'll be sold for your scalp.
- Trial design: Double-blind, sham-controlled, 16 to 26 weeks, forty to one hundred thirty participants.
- Counting method: Terminal hairs in a tattooed one-centimeter target, photographed and read blind.
- Effect size: 18 to 26 hairs per square centimeter gained, against 2 to 9 on sham.
- The soft spot: Follow-up past a year is thin and funding often traces back to the sellers.
The marked target area is what makes those numbers usable, because hair counted by hand in an unmarked region drifts by more than the treatment effect itself.
Why does pattern hair loss respond to red light while scarring alopecias do not?
One scalp still has a follicle to work with and the other doesn't, and that single difference explains the whole split. In pattern loss dihydrotestosterone keeps shortening the growth phase until the hair is barely visible fuzz, but the follicle is downsized rather than dead. In scarring disease the body has already replaced it with connective tissue.
| Feature | Pattern Loss | Scarring Alopecia |
|---|---|---|
| Follicle | Miniaturized, still cycling | Destroyed, replaced by fibrous tissue |
| Bulge stem cells | Intact and cycling | Attacked and lost |
| Follicular openings | Visible, thick and fine hairs side by side | Absent, skin smooth and slightly shiny |
| Other signs | None beyond thinning | Redness, scaling, burning or itching |
| What light can do | Modest regrowth and thicker shafts | Nothing regrows; research aims only at slowing damage |
Light therapy only has something to act on where the bulge stem cells and dermal papilla survive, which is why a four millimetre punch biopsy is the deciding test when trichoscopy is ambiguous.
Does temporary shedding such as telogen effluvium benefit from light treatment, or does it resolve on its own?
Most of the time it resolves on its own, and that's the single most important thing to know before you buy anything in the middle of a shed. There's an attribution trap waiting here: start a device in month three, see regrowth in month six, and credit the device for what recovery was going to do anyway. Knowing the timeline protects your wallet and your patience.
- The trigger: Childbirth, high fever, surgery, a crash diet, thyroid swings, iron deficiency, or a medication change.
- The lag: The shed shows up roughly three months after the event, though it can run anywhere from one to six.
- The shed: By definition it lasts under six months, and it's often a good deal shorter than that.
- The regrowth: Restarts around six months and takes longer still before you can see it in the mirror.
Telogen effluvium reverses without treatment because the follicles never miniaturized, so a ferritin level, a full thyroid panel, and a medication review come before any device purchase.
What role can photobiomodulation play in alopecia areata and other autoimmune hair loss?
The honest answer is that the role is unproven and probably minor. This is a T-cell attack on the follicle bulb, not a slow squeeze from hormones, and the follicle survives in a paused state, which is why patches can refill years later on their own. That same habit of spontaneous regrowth is what makes the small studies here impossible to read.
The published work on red light in alopecia areata is limited to small open-label series and split-scalp reports without sham arms, which can't be separated from a condition where many limited patchy cases regrow within a year on their own.
How much hair must still be present for a device to have anything to work with?
Think of it as a rescue operation, not a resurrection. Your scalp carries roughly 100,000 follicles and hides about half the loss in an area before anyone notices, and that hidden stretch is exactly the window where light still has something to act on. Once it closes, it doesn't reopen.
- Visible threshold: Thinning rarely registers to the eye until about 50 percent of an area is gone.
- Diameter diversity: Thick, medium, and wispy hairs in one field means the follicles are still alive.
- Smooth and shiny: No follicular openings and no vellus fuzz means fibrosis, and light won't touch it.
- Location: Vertex and mid-scalp respond better than the frontal hairline and the temples.
A follicle dormant for many years is unlikely to be recoverable, so someone three years into thinning is a far better candidate than someone who went bald at twenty-five and is now fifty.
Which Norwood and Ludwig stages were actually studied in the trials behind device clearance?
The stages printed on the box aren't a marketing choice, they're a description of who was enrolled. Norwood grades male pattern loss from an unchanged juvenile hairline through temporal recession and crown thinning to the horseshoe fringe, and Ludwig grades female loss by how wide the central part has become. Advanced stages were left out because a scalp with nothing left to stimulate would have watered down the measurable effect.
Read the stage range on a clearance as an enrolment criterion rather than a legal restriction, because a person at Norwood 6 is buying evidence collected on Norwood 3 subjects that does not apply to him.
Do age, sex, and hair color change who responds?
Duration of loss beats chronological age every time. A sixty-year-old whose crown started thinning two years ago has more recoverable follicles than a thirty-year-old who's been losing hair since college, so the useful question isn't how old you are, it's how long this has been going and how fast.
Women need ferritin, thyroid function, vitamin D, and androgen levels checked before anyone concludes the loss is hereditary, particularly around perimenopause when declining estrogen unmasks androgen sensitivity and the shedding can accelerate suddenly.
Which health conditions, medications, or skin conditions make someone a poor candidate?
Outright contraindications are few, because these are low-power devices whose worst common side effects are warmth, mild dryness, and a brief shed in the first month. What should stop you is a drug interaction or a diagnosis nobody checked. Get those wrong and you'll spend a year treating a symptom while the actual cause keeps working.
- Photosensitizing drugs: Isotretinoin, tetracyclines, some thiazides, methotrexate, amiodarone, certain psychiatric drugs, St John's wort.
- Active scalp disease: Quiet seborrheic dermatitis, psoriasis, folliculitis, sunburn, or open lesions first.
- Pigmented lesions: A melanoma history or a suspicious scalp lesion needs dermatology review before repeated exposure.
- The missed cause: Untreated hypothyroidism, low ferritin, vitamin D deficiency, or a severely restricted diet.
Screening bloodwork before purchase is the highest value step in the whole plan, because the most common reason a candidate fails is that the real driver of the loss was never hereditary.
When is a person better served by a transplant, a prescription drug, or an in-office procedure instead?
Match the tool to the stage and this stops being a hard decision. Once an area is genuinely bare, surgery is the only thing that puts hair where none exists; while follicles are still miniaturizing, medication is the heavier lever and light therapy is the layer you add to it. Most people who use a device well are already on something else.
| Where You Are | The Right Tool | Typical Cost |
|---|---|---|
| Bare scalp, no follicular openings | Follicular unit extraction or strip surgery | One four-figure to five-figure fee |
| Active miniaturization | Topical minoxidil 5 percent, oral finasteride or dutasteride | A few hundred dollars a year |
| Miniaturization, wants an in-office option | Platelet-rich plasma, maintenance every three to six months | A few thousand dollars a year |
| Can't tolerate or won't take a systemic drug | Light therapy, three sessions a week | Several hundred to several thousand, one time |
Hold transplant surgery until six to twelve months of medical stabilization, because grafts placed into a field that's still collapsing leave an island of transplanted hair surrounded by new bare scalp within a few years.
